Cidofovir Anhydrous: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Cidofovir Anhydrous. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Proteinuria (≥ 30 mg/dl) | 101% |
| Nausea +/- vomiting | 79% |
| Proteinuria (≥ 100 mg/dl) | 68% |
| Neutropenia (< 750 cells/mm3 ) | 50% |
| Asthenia | 50% |
| Headache | 34% |
| Rash | 34% |
| Neutropenia (≤ 500 cells/mm3 ) | 33% |
| Alopecia | 31% |
| Diarrhea | 30% |
| Pain | 29% |
| Creatinine elevation (> 1.5 mg/dl) | 28% |
| Anemia | 28% |
| Anorexia | 26% |
| Chills | 25% |
| Increased cough | 22% |
| Decreased serum bicarbonate (≤ 16 meq/l) | 21% |
| Oral moniliasis | 21% |
| Fever | 19% |
| Infection | 16% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
VISTIDE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF VISTIDE HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS.
Source: FDA labeling via NIH DailyMed (set 90639fc6…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.